%0 Journal Article %A Frederik Plesner Lyngse %A Laust Hvas Mortensen %A Matthew J. Denwood %A Lasse Engbo Christiansen %A Camilla Holten Møller %A Robert Leo Skov %A Katja Spiess %A Anders Fomsgaard %A Maria Magdalena Lassaunière %A Morten Rasmussen %A Marc Stegger %A Claus Nielsen %A Raphael Niklaus Sieber %A Arieh Sierra Cohen %A Frederik Trier Møller %A Maria Overvad %A Kåre Mølbak %A Tyra Grove Krause %A Carsten Thure Kirkeby %T SARS-CoV-2 Omicron VOC Transmission in Danish Households %D 2021 %R 10.1101/2021.12.27.21268278 %J medRxiv %P 2021.12.27.21268278 %X The Omicron variant of concern (VOC) is a rapidly spreading variant of SARS-CoV-2 that is likely to overtake the previously dominant Delta VOC in many countries by the end of 2021.We estimated the transmission dynamics following the spread of Omicron VOC within Danish households during December 2021. We used data from Danish registers to estimate the household secondary attack rate (SAR).Among 11,937 households (2,225 with the Omicron VOC), we identified 6,397 secondary infections during a 1-7 day follow-up period. The SAR was 31% and 21% in households with the Omicron and Delta VOC, respectively. We found an increased transmission for unvaccinated individuals, and a reduced transmission for booster-vaccinated individuals, compared to fully vaccinated individuals. Comparing households infected with the Omicron to Delta VOC, we found an 1.17 (95%-CI: 0.99-1.38) times higher SAR for unvaccinated, 2.61 times (95%-CI: 2.34-2.90) higher for fully vaccinated and 3.66 (95%-CI: 2.65-5.05) times higher for booster-vaccinated individuals, demonstrating strong evidence of immune evasiveness of the Omicron VOC.Our findings confirm that the rapid spread of the Omicron VOC primarily can be ascribed to the immune evasiveness rather than an inherent increase in the basic transmissibility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFrederik Plesner Lyngse: Independent Research Fund Denmark (Grant no. 9061-00035B.); Novo Nordisk Foundation (grant no. NNF17OC0026542); the Danish National Research Foundation through its grant (DNRF-134) to the Center for Economic Behavior and Inequality (CEBI) at the University of Copenhagen. Laust Hvas Mortensen is supported in part by grants from the Novo Nordisk Foundation (grant no. NNF17OC0027594, NNF17OC0027812). Matthew Denwood, Lasse Christiansen and Carsten Kirkeby receive funding from Statens Serum Institut as part of the Expert Group for Mathematical Modelling of COVID-19.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data used in this study are available under restricted access due to Danish data protection legislation. The data are available for research upon reasonable request to The Danish Health Data Authority and Statens Serum Institut and within the framework of the Danish data protection legislation and any required permission from Authorities. We performed no data collection or sequencing specifically for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study are available under restricted access due to Danish data protection legislation. The data are available for research upon reasonable request to The Danish Health Data Authority and Statens Serum Institut and within the framework of the Danish data protection legislation and any required permission from Authorities. We performed no data collection or sequencing specifically for this study. %U https://www.medrxiv.org/content/medrxiv/early/2021/12/27/2021.12.27.21268278.full.pdf